Sharp Therapeutics Corp

Sharp Therapeutics Corp has a highly liquid balance sheet, with a current ratio of 11.6, indicating strong short-term liquidity. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure. However, the company is experiencing negative cash flows, with an operating cash flow of -$15,364 million and a free cash flow of -$21,098 million, which may pressure liquidity over time. Profitability metrics are negative, with a return on equity of -8.33% and a return on assets of -7.61%. These figures are below the industry median for biotechnology and medical research firms, indicating underperformance relative to peers. The company reported a net loss of $21,098 million, which is a significant drag on shareholder value. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financial filings. This lack of diversification increases exposure to market-specific risks, particularly in the healthcare diagnostics sector, which is subject to regulatory and reimbursement pressures. Growth trajectory is currently negative, with the company reporting declining operating income and net income. There are no disclosed plans for significant revenue growth in the near term, and the company is not investing in capital expenditures, as long-term debt remains at zero. This suggests a lack of investment in future growth opportunities. Risk factors include liquidity risk due to negative operating and free cash flows, though the company has no immediate filing-based liquidity or dilution flags. The absence of long-term debt and a low dilution risk score provide some buffer, but the company's financial performance remains a concern. Recent events include the latest financial filing, which shows continued losses and negative cash flows. There are no disclosed material events or regulatory actions in the latest filings, but the company's financial position remains weak.